Interní Med. 2002; 4(8): 381-385

Terapie osteoporózy

prof. MUDr. Vladimír Palička CSc1, doc. MUDr. Pavel Živný CSc1, MUDr. Antonín Pohlídal2
1 Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové
2 Ústav klinické biochemie, FNsP Ostrava

Keywords: osteoporosis, HRT, bisphosphonates, calcitonin, SERM.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palička V, Živný P, Pohlídal A. Terapie osteoporózy. Interní Med. 2002;4(8):381-385.

Osteoporóza představuje jedno z populačně nejzávažnějších onemocnění moderní společnosti a jeho léčba vyčerpává značnou část rozpočtu zdravotnictví. Musí být proto racionální a řádně zdůvodněná. Jejím základem je aktivizace pacienta, zdravý životní styl s dostatkem přiměřeného pohybu a zdravou výživou s dostatkem vápníku a vitaminu D. Suplementace těchto dvou přípravků je obvykle nezbytná. Kauzální léčbou primární postmenopauzální osteoporózy je hormonální suplementace, především estrogenní. K velmi účinným způsobům léčby patří bisfosfonáty, selektivní modulátory estrogenních receptorů a kalcitonin. Perspektivní budou stimulátory novotvorby (parathormon, stroncium) a růstové faktory. Nedořešená je otázky délky nezbytné léčby.

Therapy of Osteoporosis

Osteoporosis represents a large problem in health care, both from the medical social and economic point of view. The first and very important step in its therapy is the -activation of patient- in the sense of a healthy life style, appropriate physical activity and an increase of calcium in their diet. The supplementation of calcium and vitamin D is a very important first step in the therapy. For primary postmenopausal osteoporosis hormonal supplementation (estrogen) is usually the best solution. Bisphosphonates, calcitonin and selective estrogen receptor modulators are very important drugs for osteoporosis treatment. Stimulation of osteosynthesis by PTH or stroncium is a possible future therapy. The duration of therapy is still an open-ended question.

Download citation

References

  1. Broulík P. Osteoporóza. Praha Maxdorf 1999: 172.
  2. Kocián J. Osteoporóza a osteomalacie. Praha Triton 1995: 171.
  3. Lahoš J. Osteoporóza. Praha Galén 1995: 172.
  4. Marcus R, Feldman D, Kelsey J. Osteoporosis. New York Academic Press 1996: 1373.
  5. Štěpán J. Syndrom osteoporózy. Praha Avicenum 1990: 202.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.